322 related articles for article (PubMed ID: 27769526)
1. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
Gueli Alletti S; Petrillo M; Vizzielli G; Bottoni C; Nardelli F; Costantini B; Quagliozzi L; Gallotta V; Scambia G; Fagotti A
Gynecol Oncol; 2016 Dec; 143(3):516-520. PubMed ID: 27769526
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
3. Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back.
Gueli Alletti S; Vizzielli G; Lafuenti L; Costantini B; Fagotti A; Fedele C; Cianci S; Perrone E; Gallotta V; Rossitto C; Scambia G
J Minim Invasive Gynecol; 2018; 25(5):816-822. PubMed ID: 29269126
[TBL] [Abstract][Full Text] [Related]
4. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
5. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
[TBL] [Abstract][Full Text] [Related]
6. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
9. Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study.
Gallotta V; Petrillo M; Conte C; Vizzielli G; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Carbone V; Scambia G
J Minim Invasive Gynecol; 2016; 23(5):769-74. PubMed ID: 26995493
[TBL] [Abstract][Full Text] [Related]
10. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
11. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
12. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
13. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
15. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
18. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
20. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]